Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P.B. Duell, M.R. Malinow.
Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease.
Curr Opin Lipidol, 8 (1997), pp. 28-34
[2.]
Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[3.]
M.J. Peterschmitt, J.R. Simmons, H.L. Levy.
Reduction of false negative results in screening of newborns for homocystinuria.
N Engl J Med, 341 (1999), pp. 1572-1576
[4.]
M.S. Morris, P.F. Jacques, J. Selhub, I.H. Rosenberg.
Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey.
Am J Epidemiol, 152 (2000), pp. 140-148
[5.]
X. Pintó, M.A. Vilaseca, I. Ferrer, C. Mainou, M. Palá, J.F. Meco, et al.
Hyperhomocisteinemia as a risk factor for premature coronary artery disease. Relation with vitamin status and the C677T mutation of the MTHFR gene.
Netherlands J Med, 52 (1998), pp. 30
[6.]
M.Y. Tsai, B.G. Welge, N.Q. Hanson, M.K. Bignell, J. Vessey, K. Schwichtenberg, et al.
Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases.
Atherosclerosis, 143 (1999), pp. 163-170
[7.]
G.N. Welch, J. Loscalzo.
Mechanisms of disease: Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050. (Ross R. Atherosclerosis – an inflammatory disease.
N Engl J Med, 340 (1999), pp. 115-126
[8.]
K.S. McCully.
Vascular pathology of homocist(e)inemia: implications for the pathogenesis of atherosclerosis.
Am J Pathol, 56 (1969), pp. 11-28
[9.]
J. Campistol, J. Caritg, S. Ruiz, M.A. Vilaseca, F. Kirkham, H.J. Blom.
Fatal haemorrhagic infarct in an infant with homocystinuria.
Develop Med Child Neurol, 41 (1999), pp. 132-135
[10.]
K.S. Woo, P. Chook, Y.I. Lolin, J.E. Sanderson, C. Metreweli, D.S. Celermajer.
Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia.
J Am Coll Cardiol, 34 (1999), pp. 2002-2006
[11.]
H. Refsum, P.M. Ueland, O. Nygard, S.E. Vollset.
Homocysteine and cardiovascular disease.
Annu Rev Medicine, 49 (1998), pp. 31-62
[12.]
J.W. Eikelboom, E. Lonn, J. Jr. Genest, G. Hankey, S. Yusuf.
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.
Ann Intern Med, 131 (1999), pp. 363-375
[13.]
S.S. Kang, P.W. Wong, H.Y. Cook, M. Norusis, J.V. Messes.
Proteinbound homocyst(e)ine: a possible risk factor for coronary artery disease.
J Clin Invest, 77 (1986), pp. 1482-1486
[14.]
J.J. Genest, J.R. McNamara, D.N. Salem, P.W. Wilson, E.J. Schaefer, M.R. Malinow.
Plasma homocyst(e)ine levels in men with premature coronary artery disease.
J Am Coll Cardiol, 16 (1990), pp. 1114-1119
[15.]
M.J. Stampfer, M.R. Malinow, W.C. Willett, L.M. Newcomer, B. Upson, D. Ullmann, et al.
A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.
JAMA, 268 (1992), pp. 877-881
[16.]
C.J. Boushey, S.A. Beresford, G.S. Omenn, A.G. Motulsky.
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.
JAMA, 274 (1995), pp. 1049-1057
[17.]
O. Nygard, S.E. Vollset, H. Refsum, I. Stensvold, A. Tverdal, J.E. Nordrehaug, et al.
Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study.
JAMA, 274 (1995), pp. 1526-1533
[18.]
C. Fernández-Miranda, J.L. Aranda, P. Gómez González, P. Díaz-Rubio, J. Estenoz, A. Gómez de la Cámara.
La hiperhomocisteinemia es frecuente en pacientes con enfermedad coronaria. Estudio de 202 enfermos.
Med Clin (Barc, 113 (1999), pp. 407-410
[19.]
A.G. Bostom, I.H. Rosenberg, H. Silbershatz, P.F. Jacques, J. Selhub, R.B. D’Agostino, et al.
Nonfasting plasma total homocysteine and stroke incidence in elderly persons: the Framingham Study.
Ann Int Med, 131 (1999), pp. 352-355
[20.]
Pintó X, Vilaseca MA, García-Giralt N, Ferrer I, Palá M, Meco JF| |xet al. Homocysteine and the MTHFR 677C ® T allele in Spanish patients with premature coronary artery disease. Case control and family studies. Eur J Clin Invest (en prensa).
[21.]
R. Clarke, L. Daly, K. Robinson, E. Naughten, S. Cahalane, B. Fowler, et al.
Hyperhomocysteinemia: an independent risk factor for vascular disease.
N Engl J Med, 324 (1991), pp. 1149-1155
[22.]
I.M. Graham, L.E. Daly, H.M. Refsum, K. Robinson, L.E. Brattstrom, P.M. Ueland, et al.
Plasma homocysteine as a risk factor for vascular disease: The European concerted action project.
JAMA, 277 (1997), pp. 1775-1781
[23.]
E.K. Hoogeven, P.J. Kostense, C. Jakobs, J.M. Dekker, G. Nijpels, R.J. Heine, et al.
Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study.
Circulation, 101 (2000), pp. 1506-1511
[24.]
J.H. Stein, P.E. McBride.
Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment.
Arch Intern Med, 158 (1998), pp. 1301-1306
[25.]
P.M. Ueland, H. Refsum, S.P. Stabler, M.R. Malinow, A. Andersson, R.H. Allen.
Total homocysteine in plasma or serum: methods and clinical applications.
Clin Chem, 39 (1993), pp. 1764-1779
[26.]
S. Tonstad, H. Refsum, M. Sivertsen, B. Christophersen, L. Ose, P.M. Uelan.
Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives.
Pediatr Res, 40 (1996), pp. 47-52
[27.]
M.Y. Tsai.
Laboratory assessment of mild hyperhomocysteinemia as an independent risk factor for occlusive vascular disease.
Clinical Chem, 42 (1996), pp. 492-493
[28.]
M.A. Vilaseca, D. Moyano, R. Artuch, I. Ferrer, M. Pineda, E. Cardo, et al.
Selective screening for hyperhomocysteinemia in pediatric patients.
Clin Chem, 44 (1998), pp. 662-664
[29.]
J.C. Peterson, J.D. Spence.
Vitamins and progression of atherosclerosis in hyperhomocist(e)inemia [carta].
Lancet, 351 (1998), pp. 263
[30.]
E.G.J. Vermeulen, C.D.A. Stehouwer, J.W.R. Twisk, M. Van der Berg, S.C. De Jong, A.J.C. Mackaay, et al.
Effect of homocysteine-lowering treatment with folic acid plus vitamin B6on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.
Lancet, 355 (2000), pp. 517-522
[31.]
O. Nygard, J.E. Nordrehaug, H. Refsum, P.M. Ueland, M. Farstad, S.E. Vollset.
Plasma homocysteine levels and mortality in patients with coronary artery disease.
N Engl J Med, 337 (1997), pp. 230-236
[32.]
G.S. Omenn, S.A. Beresford, A.G. Motulsky.
Preventing coronary heart disease: B vitamins and homocysteine.
Circulation, 97 (1998), pp. 421-424
[33.]
M.R. Malinow, A.G. Bostom, R.M. Krauss.
Homocyst(e)ine, diet and cardiovascular diseases. A Statement for Healthcare Professionals From de Nutrition Committee.
American Heart Association, (1999),
[34.]
Recomendaciones sobre suplementación con ácido fólico para la prevención de defectos del tubo neural.
Información Terapéutica del Sistema Nacional de Salud, 22 (1998), pp. 150-151
[35.]
P. Verhoef, F.J. Kok, D.A.C.M. Kruyssen, E.G. Schouten, C.M. Witteman, D.E. Grobbee, et al.
Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 989-995
[36.]
K. Robinson, K. Arheart, H. Refsum, L. Brattström, G. Boers, P. Ueland, et al.
Low circulating folate and vitamin B6concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease.
Circulation, 97 (1998), pp. 437-443
[37.]
J.B. Ubbink.
Vitamin nutrition status and homocysteine: an atherogenic risk factor.
Nutrition Reviews, 52 (1994), pp. 383-393
[38.]
J. Selhub, P.F. Jacques, P.W.F. Wilson, D. Rush, I.H. Rosenberg.
Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.
JAMA, 270 (1993), pp. 2693-2698
Copyright © 2001. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.